BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tajiri K, Shimizu Y. New horizon for radical cure of chronic hepatitis B virus infection. World J Hepatol 2016; 8(21): 863-873 [PMID: 27478536 DOI: 10.4254/wjh.v8.i21.863] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Kang Y, Rawat S, Duchemin N, Bouchard M, Noh M. Human Liver Sinusoid on a Chip for Hepatitis B Virus Replication Study. Micromachines 2017;8:27. [DOI: 10.3390/mi8010027] [Cited by in Crossref: 15] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
2 De Clercq E. Role of tenofovir alafenamide (TAF) in the treatment and prophylaxis of HIV and HBV infections. Biochem Pharmacol 2018;153:2-11. [PMID: 29225131 DOI: 10.1016/j.bcp.2017.11.023] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
3 Rybicka M, Bielawski KP. Recent Advances in Understanding, Diagnosing, and Treating Hepatitis B Virus Infection. Microorganisms. 2020;8. [PMID: 32942584 DOI: 10.3390/microorganisms8091416] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
4 Tewari D, Mocan A, Parvanov ED, Sah AN, Nabavi SM, Huminiecki L, Ma ZF, Lee YY, Horbańczuk JO, Atanasov AG. Ethnopharmacological Approaches for Therapy of Jaundice: Part I. Front Pharmacol 2017;8:518. [PMID: 28860989 DOI: 10.3389/fphar.2017.00518] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
5 Scott LJ, Chan HLY. Tenofovir Alafenamide: A Review in Chronic Hepatitis B. Drugs. 2017;77:1017-1028. [PMID: 28493172 DOI: 10.1007/s40265-017-0754-9] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
6 Sun S, Yang Q, Sheng Y, Fu Y, Sun C, Deng C. Investigational drugs with dual activity against HBV and HIV (Review). Exp Ther Med 2021;21:35. [PMID: 33262821 DOI: 10.3892/etm.2020.9467] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
7 Hummert P, Parsons TL, Ensign LM, Hoang T, Marzinke MA. Validation and implementation of liquid chromatographic-mass spectrometric (LC-MS) methods for the quantification of tenofovir prodrugs. J Pharm Biomed Anal 2018;152:248-56. [PMID: 29433097 DOI: 10.1016/j.jpba.2018.02.011] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
8 Yu J, Jia H, Guo X, Desta S, Zhang S, Zhang J, Ding X, Liang X, Liu X, Zhan P. Design, synthesis, and evaluation of novel heteroaryldihydropyrimidine derivatives as non‐nucleoside hepatitis B virus inhibitors by exploring the solvent‐exposed region. Chem Biol Drug Des 2020;95:567-83. [DOI: 10.1111/cbdd.13512] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
9 Chen JY, Liu LP, Xu JF. Decrease of RBM4 indicates poor prognosis in patients with hepatocellular carcinoma after hepatectomy. Onco Targets Ther. 2017;10:339-345. [PMID: 28138257 DOI: 10.2147/ott.s125250] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]